These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 24243851)

  • 1. Residual disease in AML, a target that can move in more than one direction.
    Loken MR
    Cytometry B Clin Cytom; 2014 Jan; 86(1):15-7. PubMed ID: 24243851
    [No Abstract]   [Full Text] [Related]  

  • 2. Tumor heterogeneity makes AML a "moving target" for detection of residual disease.
    Zeijlemaker W; Gratama JW; Schuurhuis GJ
    Cytometry B Clin Cytom; 2014 Jan; 86(1):3-14. PubMed ID: 24151248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How should we prevent hematologic relapse of acute promyelocytic leukemia?
    Nagai S; Takahashi T; Kurokawa M
    J Clin Oncol; 2010 Feb; 28(4):e62; author reply e63-4. PubMed ID: 19841316
    [No Abstract]   [Full Text] [Related]  

  • 4. Early assessment of clofarabine effectiveness based on measurable residual disease, including AML stem cells.
    Hanekamp D; Ngai LL; Janssen JJWM; van de Loosdrecht A; Ossenkoppele GJ; Cloos J
    Blood; 2021 Mar; 137(12):1694-1697. PubMed ID: 33171485
    [No Abstract]   [Full Text] [Related]  

  • 5. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of relapse and survival in childhood acute myeloid leukemia: role of minimal residual disease.
    Rizzari C; Cazzaniga G; Coliva T; De Angelis C; Conter V
    Expert Rev Anticancer Ther; 2011 Sep; 11(9):1391-401. PubMed ID: 21929313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia.
    Abdelhamid E; Preudhomme C; Helevaut N; Nibourel O; Gardin C; Rousselot P; Castaigne S; Gruson B; Berthon C; Soua Z; Renneville A
    Leuk Res; 2012 Mar; 36(3):316-23. PubMed ID: 22129478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease.
    Polak J; Hajkova H; Haskovec C; Cechova H; Marinov I; Mikulenkova D; Markova J; Markova M; Vitek A; Valkova V
    Neoplasma; 2013; 60(1):74-82. PubMed ID: 23067220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relapsed AML post-allogeneic hematopoietic stem cell transplantation.
    Nicholson E; Mackinnon S
    Clin Adv Hematol Oncol; 2011 Dec; 9(12):951-5. PubMed ID: 22252667
    [No Abstract]   [Full Text] [Related]  

  • 10. [Advances in minimal residual disease detection with flow cytometry in childhood acute myeloid leukemia].
    Feng JH; Xu XJ; Tang YM
    Zhonghua Er Ke Za Zhi; 2013 Mar; 51(3):231-4. PubMed ID: 23751588
    [No Abstract]   [Full Text] [Related]  

  • 11. The impact of cell heterogeneity and immunophenotypic changes on monitoring minimal residual disease in acute myeloid leukemia.
    Zelezníková T; Babusíková O
    Neoplasma; 2006; 53(6):500-6. PubMed ID: 17167719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring minimal residual disease in AML.
    Stewart CC
    Cytotherapy; 1999; 1(4):341. PubMed ID: 20426562
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical course of the disease and the level of WT1 mRNA in 191 patients with acute myeloid leukemia (AML): joint research by 23 institutions in Japan].
    Miyawaki S; Emi N; Mitani K; Oyashiki K; Kitamura K; Morishita T; Ogawa H; Komatsu N; Soma T; Tamaki T; Kosugi H; Ohnishi K; Mizoguchi H; Hiraoka A; Kodera Y; Ueda R; Morishima Y; Nakagawa M; Tobita T; Sugimoto K; Chiba S; Inoue N; Hamaguchi M; Koga D; Tamaki H; Naoe T; Sugiyama H; Takaku F
    Rinsho Ketsueki; 2005 Dec; 46(12):1279-87. PubMed ID: 16447800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A refined approach to detect and measure minimal residual disease in childhood acute myeloid leukemia by flow cytometry.
    Capolunghi F; Capponi C; De Stefani B; Luciani M; Locatelli F; Muraca M; Carsetti R
    Am J Hematol; 2014 Mar; 89(3):343-4. PubMed ID: 24265183
    [No Abstract]   [Full Text] [Related]  

  • 17. Prediction of relapse of acute myeloid leukemia in allogeneic transplant recipients by marrow CD34+ donor cell chimerism analysis.
    Scheffold C; Kroeger M; Zuehlsdorf M; Tchinda J; Silling G; Bisping G; Stelljes M; Buechner T; Berdel WE; Kienast J
    Leukemia; 2004 Dec; 18(12):2048-50. PubMed ID: 15470491
    [No Abstract]   [Full Text] [Related]  

  • 18. Effect of processing time on analysis of rare event in minimal residual disease study.
    Rai S; Bhardwaj U; Singh S; Misra A
    Indian J Pathol Microbiol; 2017; 60(3):449-451. PubMed ID: 28937402
    [No Abstract]   [Full Text] [Related]  

  • 19. Methods of Detection of Measurable Residual Disease in AML.
    Zhou Y; Wood BL
    Curr Hematol Malig Rep; 2017 Dec; 12(6):557-567. PubMed ID: 29098609
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.